Treatment outcome of different doses of rosuvastatin on PCI patients with acute coronary syndrome

Objective To explore therapeutic effect of different doses of rosuvastatin in the treatment of percutaneous transluminal coronary intervention(PCI)patients with acute coronary syndrome(ACS)and to provide evidences for ACS treatment.Methods Totally 150 ACS patients receiving PCI in a hospital from December 2013 through December 2014 were randomly divided into A,B,and C group(50 in each group)and administrated with rosuvastatin at the doses of 5,10,and 20 mg/d,respectively,for 3 months;related indicators were compared among the three groups before and after the treatment and major cardiovascular events(MACE)and adverse reactions were observed.Results After the treatment,serum levels of hypersensitive C-reactive protein(hs-CRP)were 3.85±0.39,3.68±0.41,and 2.52±0.32 mg/L and those of brain natriuretic peptide(BNP)were 341.54±72.17,325.15±80.52,and 264.26±56.49 pg/ml for the patients in group A,B,and C,with significant differences compared to those of before the treatment(all P<0.05);the contents of hs-CRP and BNP of the patients of group C were significantly lower than those of group A and B(both P<0.05).Serum levels of total cholesterol(TC),triglyceride(TG),and low-density lipoprotein(LDL-C)in the patients of group C were 3.30±0.48,1.23±0.34,and 1.83±0.20 mmol/L,all lower than those before the treatment(all P<0.05)and lower than those of group A and B(all P<0.05).No significant statistical differences in serum alanine aminotransferase(ALT)and creatine kinase(CK)were observed among the three groups before and after treatment(all P>0.05).The incidence of MACE in group C was lower than that in A and B group,but MACE incidence of the three groups showed no significant statistical difference after the treatment(χ²=4.113,P=0.128);the incidence of adverse reactions in group C also was not significantly different from that of in group A and B(Fisher's exact P=0.504).Conclusion High-dose rosuvastatin can significantly decrease inflammation and serum BNP level in ACS patients,with effective and safety regulation of serum lipids,and could be applied in the treatment of ACS patients with PCI.